Publications by authors named "Pampin-Sanchez R"
Background And Purpose Of The Study: Ustekinumab is a monoclonal antibody approved for the treatment of moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). In spite of being an effective treatment, patients may have suboptimal response, or lose it over time. In these cases, ustekinumab intravenous (IV) maintenance therapy has been explored as a rescue option.
View Article and Find Full Text PDFObjective: Recent research suggests that the use of antibiotics could reduce the efficacy of checkpoint inhibitors, in addition to other well-known factors. It could be due to gut microbiota modification, which impact over the immune system response. However, the information available so far is contradictory.
View Article and Find Full Text PDFIntroduction: Thyroid eye disease (TED) is a complex and incompletely understood rare autoimmune disorder.
Objectives: To analyze the experience and the outcomes obtained with the use of intravenous tocilizumab in the treatment of TED.
Methods: A retrospective analysis of adult patients diagnosed with active TED resistant to intravenous corticosteroids treated in a tertiary hospital between May 2012 and May 2021.
Article Synopsis
- Some COVID-19 patients with pneumonia experience a cytokine storm that worsens their condition, potentially benefiting from anti-inflammatory treatments like colchicine.
- A trial involving 240 hospitalized patients tested the effectiveness of colchicine compared to standard care in reducing serious outcomes (like mechanical ventilation and death).
- The results showed no significant difference in outcomes between those treated with colchicine and the control group, indicating that colchicine did not offer any additional clinical benefits.
Objective: Cyclin-dependent kinase 4/6 inhibitors have a synergistic effect in combination with endocrine therapy. This combination is used as first and subsequent-line treatment for advanced luminal breast carcinoma because it increases progression-free survival. We analysed clinical course and toxicity in patients treated with palbociclib in our hospital and determined potential associations between these variables and clinicopathological variables.
View Article and Find Full Text PDFObjective: Evaluation of the effectiveness of a standard dose of cefalozin 2 grams for surgical site infection (SSI) prevention in obese patients compared to non-obese patients. There is no still controversy surrounding which is the best dosage of this antibiotic in obese patients for surgical prophylaxis.
Methods: Retrospective review of men who received prophylactic cefazolin between January 1st, 2019 and June 30th, 2019 in a traumatology department of a university hospital.
Introduction: Nivolumab is a fully human programmed death control immune point 1 immune checkpoint inhibitor antibody which promotes antitumor immunity. Cutaneous toxicity associated with nivolumab, immune system related, could be linked to a more durable response in patients with squamous cell lung cancer.
Case Report: We present the case of a 62-year-old male diagnosed with metastatic squamous cell lung cancer, who was treated with nivolumab after cytotoxic chemotherapy.
Background: Disease-modifying therapies for multiple sclerosis have been developed tremendously over the last two decades.
Objective: The aim of this study was to review the short-, medium-, and long-term safety of alemtuzumab in relapsing remitting multiple sclerosis (RRMS).
Method: This retrospective observational study (2015-2019) included all patients with highly active or rapidly progressing and aggressive RRMS who were treated with alemtuzumab at the Cabueñes University Hospital.